Marked in vivo Donor Treg expansion via targeting of the IL-2/CD25 and TL1A/TNFRSF25 pathways ameliorates GVHD and preserves GVL

      Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapeutic application for the treatment of hematological malignancies, and is associated with a GVL effect. Regulation of GVHD is critical for favorable outcomes of HSCT. FoxP3+ regulatory T cells (Treg) are promising regulators of GVHD. Since the numbers of donor Tregs needed for maximal efficacy are high and ex vivo expansion presents practical/scientific challenges, strategies for in vivo manipulation would represent a significant therapeutic advance for HSCT recipients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect